Eli Lilly Expands AI Drug Discovery Partnership with Insilico Medicine

Eli Lilly has expanded its collaboration with Insilico Medicine in a deal valued at up to $2.75 billion, strengthening its push into AI-driven drug discovery.  

The agreement gives Eli Lilly exclusive rights to develop, manufacture, and commercialize a range of AI-designed drug candidates, including oral therapies currently in preclinical stages. Insilico will receive an upfront payment along with milestone-based payouts and royalties tied to future drug sales.  

The partnership builds on earlier collaborations and uses Insilico’s AI platforms to identify drug targets, simulate biological processes, and accelerate the discovery of new treatments across multiple diseases.